292 related articles for article (PubMed ID: 24030942)
1. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942
[TBL] [Abstract][Full Text] [Related]
2. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.
Imai T; Uchino S; Okamoto T; Suzuki S; Kosugi S; Kikumori T; Sakurai A;
Eur J Endocrinol; 2013 May; 168(5):683-7. PubMed ID: 23416954
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
Qi XP; Zhao JQ; Fang XD; Lian BJ; Li F; Wang HH; Cao ZL; Zheng WH; Cao J; Chen Y
BMC Cancer; 2021 Apr; 21(1):369. PubMed ID: 33827484
[TBL] [Abstract][Full Text] [Related]
4. Role of RET genetic variants in MEN2-associated pheochromocytoma.
Siqueira DR; Ceolin L; Ferreira CV; Romitti M; Maia SC; Maciel LM; Maia AL
Eur J Endocrinol; 2014 Jun; 170(6):821-8. PubMed ID: 24616415
[TBL] [Abstract][Full Text] [Related]
5. Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.
Wang YP; Li FP; Wang HH; Fang XD; Zhu ZS; Chen YL; Qi XP
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):339-347. PubMed ID: 34445950
[TBL] [Abstract][Full Text] [Related]
6. Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
Lebeault M; Pinson S; Guillaud-Bataille M; Gimenez-Roqueplo AP; Carrie A; Barbu V; Pigny P; Bezieau S; Rey JM; Delvincourt C; Giraud S; Veyrat-Durebex C; Saulnier P; Bouzamondo N; Chabbert M; Blin J; Mohamed A; Romanet P; Borson-Chazot F; Rohmer V; Barlier A; Mirebeau-Prunier D
Thyroid; 2017 Dec; 27(12):1511-1522. PubMed ID: 28946813
[TBL] [Abstract][Full Text] [Related]
7. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
[TBL] [Abstract][Full Text] [Related]
8. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China.
Qi XP; Chen XL; Ma JM; Du ZF; Fei J; Yang CP; Cheng J; Song QZ; Han JS; Jin HY; Chen ZG; Wang JQ; Yang YP; Ying RB; Liu WT; Zhao Y; Chen CY; Jiang HL; Ke HP; Zhang XN
Thyroid; 2012 Dec; 22(12):1257-65. PubMed ID: 23210566
[TBL] [Abstract][Full Text] [Related]
9. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
[TBL] [Abstract][Full Text] [Related]
10. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
[TBL] [Abstract][Full Text] [Related]
11. Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma.
Rajan S; Zaidi G; Agarwal G; Mishra A; Agarwal A; Mishra SK; Bhatia E
World J Surg; 2016 Mar; 40(3):690-6. PubMed ID: 26438242
[TBL] [Abstract][Full Text] [Related]
12. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
13. Genotype-specific development of MEN 2 constituent components in 683 RET carriers.
Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38753300
[TBL] [Abstract][Full Text] [Related]
14. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrine neoplasia type 2A. Study of a family.
Correia MJ; Lopes LO; Bugalho MJ; Cristina L; Santos AI; Bordalo AD; Pinho B; da Silva HL; Gonçalves MD; Ribeiro C; Tuna JL
Rev Port Cardiol; 2000 Jan; 19(1):11-31. PubMed ID: 10731788
[TBL] [Abstract][Full Text] [Related]
16. [Multiple endocrine neoplasia type 2].
Niccoli-Sire P; Conte-Devolx B
Ann Endocrinol (Paris); 2007 Oct; 68(5):317-24. PubMed ID: 17626779
[TBL] [Abstract][Full Text] [Related]
17. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 2.
Lodish M
Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.
Raue F; Bruckner T; Frank-Raue K
J Clin Endocrinol Metab; 2019 Oct; 104(10):4264-4272. PubMed ID: 31145454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
